When viewing this topic in a different language, you may notice some differences in the way the content is structured, but it still reflects the latest evidence-based guidance.

Arterite de células gigantes

  • Visão geral
  • Teoria
  • Diagnóstico
  • Tratamento
  • ACOMPANHAMENTO
  • Recursos
Última revisão: 20 Aug 2025
Última atualização: 24 Jun 2025

Resumo

Definição

Анамнез и осмотр

Ключевые диагностические факторы

  • presença de fatores de risco
  • cefaleia
  • sintomas de polimialgia reumática
  • idade avançada
  • claudicação de membros
  • perda súbita de visão
  • claudicação mandibular
  • sensibilidade arterial, espessamento ou nodularidade
  • ausência de pulso da artéria temporal
  • fundoscopia anormal
Полная информация

Другие диагностические факторы

  • sintomas sistêmicos
  • tosse, faringite, rouquidão
  • sintomas neurológicos
  • sopro na auscultação
  • pressão arterial assimétrica
  • sensibilidade dos ombros
  • amplitude de movimento ativa dos ombros e quadril limitada
  • edema do punho e joelho
  • dor de dente e dor ou infarto linguais
Полная информация

Факторы риска

  • idade ≥50 anos
  • sexo feminino
  • fatores genéticos
  • tabagismo
  • aterosclerose
  • fatores ambientais
Полная информация

Диагностические исследования

Исследования, которые показаны в первую очередь

  • proteína C-reativa
  • velocidade de hemossedimentação (VHS)
  • Hemograma completo
  • TFHs
  • biópsia da artéria temporal
  • ultrassonografia da artéria temporal
Полная информация

Исследования, проведение которых нужно рассмотреть

  • Exames de imagem vascular não invasivos
Полная информация

Неотложные исследования

  • tomografia por emissão de pósitrons com fluordesoxiglucose (FDG-PET) da cabeça até a metade da coxa

Алгоритм лечения

Начальные

suspeita de arterite de células gigantes

ПРОДОЛЖЕНИЕ

arterite de células gigantes confirmada

Составители

Авторы

Kenneth J. Warrington, MD
Kenneth J. Warrington

Professor of Medicine

Mayo Clinic College of Medicine

Rochester

MN

Раскрытие информации

KJW’s employer receives payments from Eli Lilly, GSK, and Kiniksa for his role as investigator in giant cell arteritis clinical trials. KJW has conducted consulting work for Sanofi, and received compensation from Roche/Genentech for lecturing. He has received honoraria and consulting fees from Chemocentryx. KJW is an author of a number of references cited in this topic.

Выражение благодарностей

Dr Kenneth J. Warrington wishes to gratefully acknowledge Dr Eric L. Matteson, a previous contributor to this topic.

Раскрытие информации

ELM’s employer has received payments from Bristol Myers Squibb and GlaxoSmithKline for his role as investigator in giant cell arteritis clinical trials; from Novartis for his role in polymyalgia rheumatica clinical trials; and from GlaxoSmithKline for his role as an advisory consultant. ELM is an author and editor for Up To Date and Paradigm, as well as an author of a number of references cited in this topic.

Рецензенты

Anisha B. Dua, MD, MPH

​Associate Professor

Northwestern University Feinberg School of Medicine

Chicago

IL

Раскрытие информации

ABD declares they have paid consultancies from Amgen, Abbvie, Novartis, GSK and Sanofi. ABD is on the board of directors for the Vasculitis Foundation.

Kuntal Chakravarty, FRCP (London), FRCP (Glasgow), FRCP (Ireland), FACP (USA), FACR (USA)

Consultant Rheumatologist

BHRT University Hospital

Queen’s Hospital

Romford

UK

Раскрытие информации

KC declares that he has no competing interests.

Peer reviewer acknowledgements

BMJ Best Practice topics are updated on a rolling basis in line with developments in evidence and guidance. The peer reviewers listed here have reviewed the content at least once during the history of the topic.

Disclosures

Peer reviewer affiliations and disclosures pertain to the time of the review.

Список литературы

Our in-house evidence and editorial teams collaborate with international expert contributors and peer reviewers to ensure that we provide access to the most clinically relevant information possible.

Основные статьи

Ponte C, Grayson PC, Robson JC, et al. 2022 American College of Rheumatology/EULAR classification criteria for giant cell arteritis. Arthritis Rheumatol. 2022 Dec;74(12):1881-9. Аннотация

Maz M, Chung SA, Abril A, et al. 2021 American College of Rheumatology/Vasculitis Foundation guideline for the management of giant cell arteritis and Takayasu arteritis. Arthritis Rheumatol. 2021 Aug;73(8):1349-65.Полный текст  Аннотация

Dejaco C, Ramiro S, Bond M, et al. EULAR recommendations for the use of imaging in large vessel vasculitis in clinical practice: 2023 update. Ann Rheum Dis. 2024 May 15;83(6):741-51.Полный текст  Аннотация

Статьи, указанные как источники

A full list of sources referenced in this topic is available to users with access to all of BMJ Best Practice.

Использование этого контента попадает под действие нашего заявления об отказе от ответственности